IGHE and neoplasm: Furthermore, we discuss how harnessing attributes of basophils using emerging clinical tools such as the basophil activation test (BAT) can help to monitor desensitization of patients who have shown hypersensitivity to anti-cancer drugs, and to predict whether cancer patients are likely to develop hypersensitivity to emerging therapies, including anti-tumor IgE antibody immunotherapies.